D-Serine & Depression: New Hope for Severe Cases
- A recent study published in the journal of Affective Disorders, lead by Lukas Sempach of the University of Basel, suggests that D-serine, when used as an adjunctive treatment,...
- The 6-week, randomized, double-blind, placebo-controlled trial involved 44 adult inpatients from basel, Switzerland, diagnosed with moderate to severe MDD.
- Although both groups experienced symptom reduction,D-serine showed a significant advantage in alleviating depressive symptoms specifically in participants with severe MDD.
Groundbreaking research indicates that D-serine could be a game-changer for those battling severe major depressive disorder (MDD). The latest study, published in the Journal of Affective Disorders, reveals that while D-serine didn’t outperform a placebo it significantly alleviated symptoms in patients with severe MDD.This study looked at 44 adult inpatients and found improvements linked too higher baseline depression severity and increased standard medication doses. The findings support D-serine’s potential as a synergistic adjunctive strategy to boost the impact of current pharmacological interventions, offering a glimmer of hope for treatments.News Directory 3 provides you with the most recent research. However,the study’s small sample size warrants further investigation into D-serine’s optimal use. Discover what’s next for depression treatments.
D-Serine May Benefit Patients With Severe Major Depressive Disorder
Updated June 8, 2025
A recent study published in the journal of Affective Disorders, lead by Lukas Sempach of the University of Basel, suggests that D-serine, when used as an adjunctive treatment, may offer therapeutic benefits for individuals with severe major depressive disorder (MDD). While the study found that D-serine did not outperform a placebo in the overall sample of patients with MDD, subgroup analysis revealed significant improvements in depressive symptoms and anhedonia among those with severe MDD.
The 6-week, randomized, double-blind, placebo-controlled trial involved 44 adult inpatients from basel, Switzerland, diagnosed with moderate to severe MDD. Participants were administered either D-serine (2 g/d) or a placebo in addition to their standard treatment. Researchers then assessed changes in depressive symptoms using the Hamilton Depression Rating Scale and other measures.
Although both groups experienced symptom reduction,D-serine showed a significant advantage in alleviating depressive symptoms specifically in participants with severe MDD. Furthermore, clinical improvements in the D-serine group were linked to higher baseline depression severity and higher doses of standard medication. No serious adverse events were reported during the trial.
“DS [D-serine] may offer therapeutic benefits for patients with severe MDD, especially when used alongside greater doses of TAU [treatment as usual] medication. These findings support the potential of DS as a synergistic adjunctive strategy to enhance the therapeutic effect of pharmacological interventions, especially in severe cases,” the authors wrote.
What’s next
The researchers caution that the study’s small sample size limits the generalizability of the findings. Further research with larger and more diverse populations is needed to confirm these results and to explore the optimal dosage and duration of D-serine treatment for severe MDD.